Collegium Pharmaceutical, Inc.
COLLNASDAQ · Healthcare · Drug Manufacturers - Specialty & GenericCheapGARPCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.
$24.21-3.78%
报价 2026-11-06
市值
$788.2M
EV
$1.79B
PE (TTM)
17.5x
预期 PE (FY2026)
3.2x
52 周区间距高点 -51.4%
$21.53$49.84
筛选结果
pipeline · 2026-11-06Keep✗ 高增长✓ Cheap✓ GARP
Cheap Pool: EV/EBITDA <= 8, P/FCF <= 12
GARP Pool: growth 10-30%, PE <= 20, EV/EBITDA <= 12, P/FCF <= 20, MC/GP <= 11
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 7.68 → 7.26（0.9x） | 3.3 |
| FY+32028-12 | 1.0x | 7.68 → 7.70（1.0x） | 3.1 |
毛利率 59% · TTM 收入 $815M · 基数 EPS 7.68（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| COLLCollegium Pharmaceutical, Inc. | $788.2M | -3.8% | +11.9% | 59.4% | 17.5x | 3.0x | 2.4x | Cheap GARP |
| PLSEPulse Biosciences, Inc. | $3.87B | +0.4% | +1900.0% | 51.6% | – | – | – | 高增长 |
| PCRXPacira BioSciences, Inc. | $1.45B | +0.0% | +3.3% | 77% | 103.2x | 14.4x | 8.1x | |
| INVAInnoviva, Inc. | $1.38B | -0.7% | +10.3% | 78.9% | 6.0x | 3.0x | 8.2x | |
| CRONCronos Group Inc. | $1.33B | -3.0% | +53.8% | 53.7% | 18.4x | 14.9x | 25.6x | 高增长 |
| AMPHAmphastar Pharmaceuticals, Inc. | $1.21B | +3.0% | +3.6% | 49.5% | 9.0x | 7.0x | 10.0x | Cheap |
| GDRXGoodRx Holdings, Inc. | $1.2B | +0.6% | +0.6% | 89.5% | 66.7x | 8.4x | 8.2x | |
| NKTRNektar Therapeutics | $1.07B | +3.1% | -5.3% | 99.4% | – | – | – | |
| MDXGMiMedx Group, Inc. | $483M | +0.9% | -30.8% | 82.6% | 12.9x | 6.0x | 6.9x | |
| 同行中位数 | – | – | +3.5% | 78% | 15.7x | 7.7x | 8.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。